Seize the opportunity, strive for a new high point of cement performance, find the right track, break through the bottleneck period of the pharmaceutical company, the chairman of the board of directors points out the direction for the work in the coming year.
Release time:
2022-02-08
2021 held on February 26 , Jiang Xiaomeng, secretary of the party Committee and chairman of the group company, made a summary speech entitled "seize the opportunity and strive for a new high point in cement performance" in view of the current market situation and existing problems faced by the company. Find the track and break through the bottleneck period of pharmaceutical companies, pointing out direction and requirements for the company's work in 2022 . Jiang Xiaomeng pointed out that in
2021, the company achieved relatively ideal operating results in a complex market environment, which is not only the foundation laid by the company's industrial structure adjustment and capital investment in recent years, but also the result of the joint efforts of management departments at all levels and employees of production enterprises. The general manager's work report comprehensively analyzes and expounds the company's current business situation and future direction of efforts, which is the arrangement made by the management of the group company after close analysis and careful consideration. I hope that the management team of each enterprise will seriously understand and implement it, so as to better complete all the work in the new year. When talking about the work direction of
2022, Jiang Xiaomeng summed it up in two sentences, namely, "seize the opportunity and strive for a new high in cement performance; Find the right track and break through the bottleneck period of pharmaceutical companies". Jiang Xiaomeng said that the Central Economic Work Conference pointed out that the economic work in
2022should "take the lead in stability and seek progress in stability" and "continue to implement a proactive fiscal policy and a prudent monetary policy". The economic work conferences of all provinces have also released relevant positive signals, which shows that the government will take measures to stimulate the economy; as the epidemic situation in major foreign power coal supply countries is relatively under control, energy prices have also entered a downward channel, which will reduce the cost pressure of raw fuel materials for cement enterprises. In recent years, cement enterprises under the peak have continuously increased their investment in equipment and technology upgrading, and cost control is expected to be significantly improved. The superposition of these internal and external factors will bring opportunities to the peak cement plate. Therefore, all cement enterprises should take stock of the situation, seize the favorable opportunity and do a good job in the homework of "cement ", that is, extend the cement industry chain to the upstream and downstream, realize vertical integration, and take aggregate, machine-made sand and solid and hazardous waste treatment as the new profit-making points of cement plate, so as to create better business performance. For the peak medicine sector, Jiang Xiaomeng believes that peak medicine
20has developed over the years, accumulated a number of talents and technologies, cultivated some new products, and its product structure has been continuously adjusted according to market changes. Although the current centralized band procurement has an impact on drug prices, the sales growth of the winning varieties is also conducive to the dilution of costs, which has been reflected in the market sales of peak pharmaceutical olopatadine eye drops. From the perspective of industry development trends, as the global failure rate of new drug research and development is getting higher and higher, and it is becoming more and more difficult to develop new targets, improved new drugs that upgrade existing drugs may be another blue ocean for pharmaceutical companies. At the same time, the continuous improvement of environmental protection requirements make API production resources increasingly scarce, the advantages of the North Carolina API base of Peak Pharmaceuticals will become more and more obvious. Therefore, the new track of peak pharmaceutical industry should be developed to eye drops and ophthalmic drugs, to improved new drugs, and to the integration of raw materials and preparations. Jiang Xiaomeng said that while identifying its own advantages and efforts, it is also necessary to see its own shortcomings. There is still room for improvement in many indicators and labor productivity of Jianfeng cement enterprises, and the research and development speed of Jianfeng Pharmaceutical products is not as fast as expected, which requires management teams at all levels to break away from their inherent thinking and further improve their ability and methods of solving problems in terms of management, communication, coordination and team unity. Through the joint efforts of all employees and doing a good job in accordance with the company's deployment, we will certainly achieve better performance in the new year. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page